ALS2CL抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P05811(ALS2CL Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P05811(ALS2CL Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

ALS2CL antibody targets the ALS2 C-terminal-like (ALS2CL) protein, a less characterized homolog of alsin encoded by the ALS2 gene. Alsin, associated with autosomal recessive forms of amyotrophic lateral sclerosis (ALS) and hereditary spastic paraplegia, plays roles in endosomal trafficking and neuronal maintenance. ALS2CL shares structural similarities with alsin’s C-terminal region, including a VPS9 domain implicated in guanine nucleotide exchange for Rab5 GTPase, a regulator of early endosome dynamics. However, ALS2CL lacks the N-terminal domains critical for alsin’s full functionality, suggesting distinct or complementary roles.

The ALS2CL protein is expressed in various tissues, including the brain, but its precise physiological functions remain unclear. Studies hypothesize its involvement in intracellular vesicle trafficking, receptor signaling, or cytoskeletal organization, potentially intersecting with pathways linked to neurodegeneration. ALS2CL antibodies are primarily used in research to detect and characterize the protein’s expression, localization, and interactions, aiding in elucidating its biological significance.

Interest in ALS2CL antibodies stems from their potential to uncover ALS2CL’s relationship to neurodegenerative diseases, particularly ALS, though direct pathological associations are yet unproven. These tools are crucial for advancing understanding of ALS2CL’s role in cellular processes and its possible contribution to disease mechanisms when dysregulated. Current research focuses on validating antibody specificity and exploring ALS2CL’s functional overlap with alsin in model systems.